Acute Ischemic Cerebrovascular Syndrome
Diagnostic Criteria

Chelsea S. Kidwell, MD; Steven Warach, MD, PhD

Background—Existing diagnostic classification systems for cerebrovascular disease are based primarily on clinical impression of temporal features, clinical syndrome, inferred localization, or ischemic mechanism. Diagnostic certainty of the ischemic pathology based on supportive or refuting laboratory or radiological evidence has been of secondary importance.

Summary of Comment—Acute ischemic cerebrovascular syndrome (AICS) describes a spectrum of clinical presentations that share a similar underlying pathophysiology: cerebral ischemia. Diagnostic criteria for AICS incorporate prior classification systems and currently available information provided by neuroimaging and laboratory data to define 4 categories ranging from “definite AICS” to “not AICS,” which define the degree of diagnostic certainty.

Conclusions—Clinical trials testing new treatments for acute ischemic stroke or secondary stroke prevention should limit enrollment to patients with “definite” AICS whenever feasible. (Stroke. 2003;34:2995-2998.)

Key Words: brain imaging | classification | diagnosis

Background: Classification and Diagnostic Criteria
The purpose of a disease classification system is to delineate meaningful descriptions of clinicopathophysiological phenomena. Such a classification system provides salient diagnostic criteria that may then be employed in clinical practice to optimize patient management and in clinical investigations to categorize research subjects. Ideally, classification schemes incorporate information along 2 parallel lines: (1) characterization of syndromes based on clinical observations of symptomatology and disease progression and (2) characterization of the underlying pathophysiology and disease mechanism confirmed by pathological, laboratory, electrophysiological, genetic, or radiological data.

Existing classification systems for cerebrovascular disease are based primarily on temporal features of the symptoms (eg, completed, evolving, transient), the syndrome of clinical deficits, the inferred localization, and etiology of the stroke.1–3 The degree of certainty about the diagnosis of the acute ischemic syndrome has not been addressed in these classification systems.1–3 These schemes have relied primarily on bedside clinical impression, with supportive or refuting laboratory or radiological evidence relegated to secondary in importance or not incorporated at all. In recent years, as sophisticated paraclinical diagnostic techniques have developed, controversy has arisen regarding the utility and accuracy of definitions that are based solely on clinical manifestations and an arbitrarily assigned time window rather than tissue changes and pathophysiological processes.

Role of Neuroimaging and Laboratory Studies in Redefining a Disease
Advanced diagnostic techniques, including neuroimaging studies, play an ever-increasing role in the evaluation, diagnosis, and management of patients with neurological disease and in particular cerebrovascular disease. MRI in particular has become a valuable, noninvasive tool for diagnosis of brain tumors, central nervous system inflammatory processes, and cerebrovascular disorders. In the case of multiple sclerosis (MS), MRI has now become an integral component of the new diagnostic criteria for “definite MS,” “possible MS,” or “not MS.”4 In patients with clinically isolated syndromes suggestive of MS, the new MRI criteria more than doubled the rate of diagnosis of MS within 1 year of presentation and demonstrated a high degree of accuracy at 3 years.5

In the realm of cerebrovascular disease, modern neuroimaging techniques have made early paraclinical confirmation of tissue and vascular pathology possible and feasible. The introduction of CT in the 1970s transformed acute stroke evaluation, providing the first reliable method to differentiate hemorrhagic from ischemic events. In the 1990s, the clinical implementation of advanced MR techniques further revolutionized acute stroke evaluation, providing a means to rapidly identify acute ischemia as well as hemodynamic compromise with the potential to provide a practical means to identify ischemic penumbral tissue in the hyperacute stroke setting.6,7

Received March 13, 2003; final revision received June 14, 2003; accepted July 23, 2003.
From the University of California at Los Angeles Stroke Center and Department of Neurology, University of California at Los Angeles Medical Center (C.S.K.), and National Institutes of Health, National Institute of Neurological Disorders and Stroke, Stroke Branch, Bethesda, Md (S.W.).
Correspondence to Dr Steven Warach, National Institutes of Health, National Institute of Neurological Disorders and Stroke, Stroke Branch, 10 Center Dr, MSC 1063, Bethesda, MD 20892-4129. E-mail warachs@ninds.nih.gov
© 2003 American Heart Association, Inc.
Stroke is available at http://www.strokeaha.org DOI: 10.1161/01.STR.0000098902.69855.A9

2995
Problem of Defining Transient Ischemic Attack and Ischemic Stroke

In the 1950s, an arbitrary distinction was made between completed stroke versus transient ischemic attack (TIA), with TIA defined as neurological symptoms of vascular etiology that resolve within 24 hours. Distinctions were based primarily on time-based resolution of symptoms and the assumption that no permanent brain injury has occurred if the clinical deficit resolves. A growing body of data from neuroimaging studies has now called into question this previous assumption and definition. In the 1970s and 1980s, a large number of studies employing CT and conventional MR sequences suggested that a subgroup of patients with transient deficits had a relevant infarct on neuroimaging studies, although a temporal link could not be definitively established.

In the last few years, advanced MRI techniques employing diffusion-weighted imaging (DWI) have clarified and extended these findings. Aggregate data from 7 observational studies encompassing 288 patients have clearly demonstrated that almost one half of patients with clinical TIA syndromes have a DWI abnormality (overall frequency across all studies, 49%; range, 35% to 67%). Although the majority of these studies suggest that the likelihood of DWI positivity increases with increasing symptom duration, this relationship is not absolute. While these lesions may resolve in some cases, the majority of patients have imaging evidence of permanent ischemic injury. Moreover, recent studies employing MR spectroscopic techniques suggest that abnormalities can be identified in the majority of patients with transient ischemic symptoms. In part as a result of these neuroimaging findings, the TIA Working Group has now called for a redefinition of TIA based on tissue pathophysiology rather than arbitrary time cutoffs.

Not all acute focal neurological deficits are of cerebrovascular origin; in fact, a substantial proportion of transient neurological deficits are probably not ischemic in nature (eg, isolated dizziness, numbness). The risk of erroneous clinical trial conclusions from inclusion of patients without pathological confirmation has been of necessity ignored in the era before highly sensitive hyperacute brain imaging of ischemia. The fields of stroke diagnostics and clinical trials have matured to the point at which bedside inference alone is an insufficient basis of clinical trial inclusion and patient management.

Acute Ischemic Cerebrovascular Syndrome: Diagnostic Criteria

As our understanding of the underlying pathophysiology of cerebral ischemia has evolved, it has become clear that previous classification schemes and definitions may not accurately reflect the full clinicopathophysiological phenomenon. Frequently, a discrepancy emerges between historical definitions based on clinical symptomatology and new imaging or laboratory data. The findings from DWI in patients with clinical TIA syndromes provide a strong impetus to abandon rigid time-based disease definitions in favor of pathologically meaningful definitions.

While terms such as TIA retain some clinical utility, it is important to recognize that these entities represent arbitrary categories within the continuum of ischemic cerebrovascular disease. The attempt to distinguish categories based on temporal profiles is confusing at best and misleading at worst. Moreover, the attempt to distinguish them on the basis of neuroimaging or laboratory findings alone may also be a moving target; as technological advances continue, blood biomarkers and neuroimaging techniques will likely be able to identify more and more subtle evidence of ischemia.

Following the lead of our cardiology colleagues, from a clinical and practical standpoint, it may be more useful to invoke a more global and encompassing term, acute ischemic cerebrovascular syndrome (AICS), in a manner analogous to the acute coronary syndrome. Subcategories, ranging from “definite” to “not,” incorporate the diagnostic certainty afforded by a combination of the clinical features and the supportive diagnostic laboratory and neuroimaging data (Table).

This new classification scheme offers a number of important advantages over prior schemes and terminology. Most importantly, it incorporates the evidence-based diagnostic certainty offered by neuroimaging techniques as used in the new MS classification scheme. Previous studies have suggested that the diagnosis of cerebrovascular ischemia is often difficult, particularly for nonneurologists or if symptoms have resolved by the time of evaluation. This type of diagnostic certainty is important in clinical research studies, providing universally applicable and standardized definitions. For example, phase II trials or studies employing risky therapies could be limited to the “definite” or “definite and probable” categories, optimizing the risk/benefit ratio and increasing the power of a study to detect a meaningful benefit by including only the “definite” target population.

In addition, this classification would be useful in routine clinical stroke care. In the acute setting, it would provide a framework for patient triage and stroke team activation. It also offers the advantage of emphasizing the similar underlying etiology (risk factors), pathophysiology, and general prognosis for recurrence of any cerebral ischemic event. This is important for long-term prevention and treatment strategies.

It is important to note that this scheme should in no way supersede the importance of accurate classification and identification of the underlying mechanism and pathophysiology of each individual event; rather, the new scheme should provide a framework on which to base further investigation and description.

This new classification scheme may pose some important challenges. As technology evolves, the sensitivity and specificity of diagnostic tests will continue to improve. Over time, the “possible” and “probable” categories may no longer be necessary. Furthermore, testing the absolute sensitivity and specificity of this scheme against an independent standard may not be possible, since all available clinical and paraclinical data are used in the determinations. The validity and utility of this classification will rest heavily on its practical application and on interrater agreement. We also recognize that the term acute implies a time criterion, an implication somewhat opposed to the purpose of the new classification scheme. A meaningful definition of acute is the time period...
within which occur the majority of events that might be considered for emergent intervention or treatment (proven, empirical, or investigational). In our proposal, most events referred to as acute will have occurred within the prior 7 days. The choice of 1 week has support from the physiological data that the decreased apparent diffusion coefficient characteristic of acute ischemic brain injury is common in the first week but rarely seen after 7 days from the time of onset.23

Conclusions

Prior classification schemes for cerebrovascular disease, based solely on temporal features and clinical symptomatology, fail to incorporate currently available information provided by neuroimaging and laboratory data. The term acute ischemic cerebrovascular syndrome describes a spectrum of clinical presentations that share a similar underlying pathophysiology: cerebral ischemia. The new criteria for this syndrome define 4 categories ranging from “definite AICS” to “not AICS,” which incorporate the degree of diagnostic certainty afforded by advanced imaging and laboratory techniques. Clinical trials testing new treatments for acute ischemic stroke or secondary stroke prevention should limit enrollment to patients with “definite” or “probable” AICS. When highly sensitive diagnostic tests are routinely available within the practical constraints of the trial, enrollment should be limited to patients with only “definite” AICS.

References


19. Caplan LR. Are terms such as completed stroke or RIND of continued usefulness? Stroke. 1983;14:431–433.


Acute Ischemic Cerebrovascular Syndrome: Diagnostic Criteria
Chelsea S. Kidwell and Steven Warach

Stroke. 2003;34:2995-2998; originally published online November 6, 2003;
doi: 10.1161/01.STR.0000098902.69855.A9
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://stroke.ahajournals.org/content/34/12/2995

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/